Australia's Noxopharm Unveils TLR8 Enhancement Method, Boosting Activity by Over 200-Fold
Olivier Laczka, CEO of Australian biotechnology company Noxopharm Limited, introduced new advances i...
Ractigen Therapeutics' saRNA Reduces Fat by 45%, Accepted for ADA 2026 Poster Presentation
Ractigen Therapeutics announced that the latest research abstract on its first-in-class small activa...
Antengene Presents ATG-207 Immune Tolerance Data at EULAR
Antengene Corporation Limited (HKEX: 6996.HK) presented preclinical data for ATG-207, an alpha-maske...
Korea Dayspring Pharma Announces Positive Phase II Clinical Results for CG2001 in Treating Androgenetic Alopecia
Dayspring Pharma announced positive top-line results from its Phase II clinical trial of the candida...
China's OriCell GPC3 CAR-T Approved for Phase II Liver Cancer Trial
OriCell Therapeutics Holdings Limited ("OriCell") announced that its self-developed autologous CAR-T...
DBV Technologies to Participate in Goldman Sachs Healthcare Conference
DBV Technologies announced that Chief Executive Officer Daniel Tassé will participate in a fireside ...
Cullinan to Present CLN-978 Clinical Data at EULAR
Cullinan Therapeutics (Nasdaq: CGEM) announced that it will present preliminary clinical data from t...
MannKind Showcases New Afrezza Pediatric Data at ADA
MannKind Corporation will present new clinical and real-world data on its products Afrezza (human in...
Denmark's Antag Presents Positive Phase 1 Results for AT7687 at ADA Annual Meeting
Antag Therapeutics presented Phase 1 and preclinical data for its GIP receptor antagonist AT7687 at ...
Novo Nordisk's CagriSema Phase III Trial Achieves Glycemic and Weight Loss Goals
Novo Nordisk announced on June 7, 2026, the results of its Phase III clinical trial for CagriSema, a...
Chinese Study: Ecnoglutide Outperforms Semaglutide in Weight Loss by 35%
Sciwind Biosciences announced interim analysis results from its head-to-head study (SLIMMER-UP-SWITC...
Amgen Reports New Results from Evolocumab Trial in the US: 25% Risk Reduction in Primary Endpoint
Amgen announced new overall and subgroup results from the Phase 3 VESALIUS-CV trial of Repatha (evol...
Curium invests €32 million in France to build a prostate cancer radiopharmaceutical production line
Curium, a global leader in nuclear medicine, announced at the "Choose France" summit held in Versail...
German ITM Publishes Single-Scan Individualized Dosimetry Data
ITM Isotope Technologies Munich SE (ITM) presented the latest single-time-point dosimetry data from ...
China's LongBio Pharma lists on HKEX with market cap of HK$10.7 billion
June 5, 2026, Shanghai – LongBio Pharma, an innovative drug developer and a portfolio company of Qim...
Veeva Summit in Denmark Showcases Falcon Platform and Vault AI Plans
At the Veeva R&D and Quality Summit Europe in Copenhagen, Denmark, Veeva Systems showcased its futur...
Rakovina's R&D Spending Rises to 70% of Operating Expenses in Q1
Rakovina Therapeutics Inc. (RKV:TSX.V) reported its first-quarter financial results for the period e...
Altesa ASM Conference Presents Vapendavir Phase 2a Study
Altesa BioSciences announced clinical study results showing that its oral investigational rhinovirus...
Cambridge University Team's AI Universal Vaccine Completes First Human Trial
Researchers at the University of Cambridge have developed a "universal vaccine" using artificial int...
Tempest Therapeutics Appoints Two Independent Directors
Tempest Therapeutics (Nasdaq: TPST) announced the appointment of Drake Richey and John Yee, M.D., M....
Australia's Imugene Presents Azer-Cel Clinical Progress at ASCO
Imugene Ltd presented clinical progress on its Azer-Cel program at the American Society of Clinical ...
Hong Kong's Lok Ma Chau Loop Hong Kong Park Plans to Prioritize Funding for Shared CDMO and Clinical Trials
In 2026, the Hong Kong Park of the Lok Ma Chau Loop Shenzhen-Hong Kong Science and Technology Innova...
Mabwell's 9MW5211 Receives NMPA Clinical Trial Approval for IBD in China
Shanghai, June 4, 2026 — Mabwell (688062.SH, 02493.HK) announced that its independently developed in...
WuXi Biologics CRDMO Formulation Plant in Singapore Tops Out with Annual Capacity of 100 Million Units
WuXi Biologics (2269.HK) announced that its formulation plant at the Contract Research, Development ...
U.S. AI Anti-Aging Company NewLimit Completes $435 Million Series C Funding
U.S. biotech company NewLimit has completed a $435 million Series C funding round, achieving a post-...
Eli Lilly and Ascidian Partner in Over $1.9 Billion Deal to Develop RNA Editors for Genetic Kidney Disease
Eli Lilly has entered into a global research collaboration with Ascidian Therapeutics to jointly dev...
AstraZeneca liver cancer combination therapy reduces risk of progression or death by 30%
Results from AstraZeneca's Phase III Emerald-3 trial showed that the regimen of durvalumab combined ...
Genetically Modified Hookworms Turned into Drug Factories by Washington University School of Medicine in St. Louis
Researchers at Washington University School of Medicine in St. Louis have successfully genetically m...
Canada's NeuroThera Acquires 54% Stake in CliniQuantum for Approximately $9.45 Million
NeuroThera Labs Inc. (TSXV: NTLX) announced the completion of its acquisition of approximately 54.01...
Novartis's Secukinumab Phase III Trial Shows Sustained Remission Rate Twice That of Placebo
Novartis has announced new data from the Phase III REPLENISH trial evaluating Cosentyx (secukinumab)...